Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 3.310 +0.010 (+0.30%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 88,181 Open 3.320 Bid (Size) 3.020 (10) Ask (Size) 3.500 (24) Prev. Close 3.300 Today's Range 3.170 - 3.392 52wk Range 0.8500 - 6.850 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Strengthen Executive Team in Anticipation of ‘Strong Growth’ into 2025 October 01, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Appoints Michael Shankman as Chief Financial Officer October 01, 2024 Via ACCESSWIRE Performance YTD +156.59% +156.59% 1 Month -9.32% -9.32% 3 Month +21.25% +21.25% 6 Month +3.76% +3.76% 1 Year +248.42% +248.42% More News Read More CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide September 27, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide September 27, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 September 27, 2024 Via ACCESSWIRE Lexaria Welcomes Industry Veteran as New CEO September 05, 2024 Via ACCESSWIRE First Results from Lexaria's Second GLP-1 Human Pilot Study August 27, 2024 Via ACCESSWIRE TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs September 20, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations September 20, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations September 20, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study September 17, 2024 Via Investor Brand Network TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program September 13, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO September 06, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO September 06, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO September 05, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study September 05, 2024 Via Investor Brand Network Lexaria Releases Strategic Letter from the Outgoing CEO September 05, 2024 Via ACCESSWIRE TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting September 03, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria Enters a Material Transfer Agreement for DehydraTECH Research September 03, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Monday's Intraday Session September 02, 2024 Via Benzinga HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results August 29, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules August 29, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’ August 27, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’ August 27, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market August 26, 2024 Via Investor Brand Network Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.